Nutriband files provisional patent application to enhance its AVERSA™ transdermal abuse deterrent technology being developed for patches containing opioids and stimulants with a potential for abuse.

Nutriband granted patent protecting its AVERSA abuse deterrent platform technology in Macao, a Special Administrative Region of the People’s Republic of China ORLANDO, Fla., April 11, 2025 (GLOBE ...

Notice of Allowance received from Chinese National Intellectual Property Administration (CNIPA) for the patent application covering its Platform AVERSA™ abuse deterrent transdermal technology ...

Love Pharma has struck a deal to acquire transdermal drug delivery technology, signing a letter of intent to buy Naltrexone Therapeutics for intellectual property covering the administration of a ...

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/1b304d/the_top_50_transde) has announced the addition of the "The Top 50 ...

Companies ally on preclinical and clinical development. Altea Therapeutics entered into a partnership with KAI Pharmaceuticals for the preclinical and clinical development of certain KAI peptides ...

BROOMALL, Pa., May 30, 2012--Transdermal Specialties Inc., a pioneer in painless, injection-free ultrasonic transdermal drug-delivery systems for the pharmaceutical industry, will unveil its ...

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in ...

Nutriband’s abuse-deterrent platform technology is now patented in 46 countries and territories covering major global markets. Nutriband (NTRB) is targeting to file for FDA approval for AVERSA™ ...